Am. J. Respir. Crit. Care Med., Volume 163, Number 7, June 2001, 1660-1668

Intratracheal Administration of Activated Protein C Inhibits Bleomycin-induced Lung Fibrosis in the Mouse

HIROKI YASUI, ESTEBAN C. GABAZZA, SHIGENORI TAMAKI, TETSU KOBAYASHI, OSAMU HATAJI, HISAMICHI YUDA, SHINO SHIMIZU, KOJI SUZUKI, YUKIHIKO ADACHI, and OSAMU TAGUCHI

Third Department of Internal Medicine, Department of Molecular Pathobiology, Mie University School of Medicine, Tsu City, Mie Prefecture, Japan

It is well recognized that activation of the coagulation system plays an important role in bleomycin (BLM)-induced lung injury and fibrosis. The protein C (PC) pathway is an important regulator of the coagulation system. In this study, we evaluated the bronchoalveolar lavage fluid (BALF) concentration of activated PC (APC) and the therapeutic effect of the intratracheal administration of APC on BLM-induced lung fibrosis in mice. APC levels in BALF were significantly lower in BLM-treated animals than in the saline-treated group. Fibrotic changes were progressive in mice treated with BLM and intratracheal instillation of vehicle (BLM/Veh) after 14 and 21 d of BLM infusion. Compared with the BLM/Veh group, histologic findings on Days 14 and 21 in mice treated with BLM and intratracheal instillation of APC (BLM/APC) showed less fibrotic lesions in the subpleural and central areas of the lung. The mean Aschcroft's fibrosis score in the BLM/Veh group was significantly (p < 0.05) higher than in the BLM/APC group. The lung hydroxyproline content on Day 21 was significantly higher (p < 0.05) in the BLM/Veh group (1.78 ± 0.07 µmol/lung weight) than in the BLM/APC (1.30 ± 0.06 µmol/lung weight) group. The ratio of plasminogen activator activity to thrombin level in BALF was significantly increased in the BLM/APC group compared with the BLM/ Veh group on Day 21. The expression of tumor necrosis factor- and interleukin-1 was significantly decreased in the lungs of the BLM/APC group compared with the BLM/Veh group on Day 14 after BLM infusion. These results showed that intratracheal APC administration inhibits the development of lung fibrosis in BLM-induced lung injury, giving further support to the important role that the PC pathway plays in the mechanism of lung fibrosis.

This article has been cited by other articles:

				N Oikonomou, A Thanasopoulou, A Tzouvelekis, V Harokopos, T Paparountas, I Nikitopoulou, W Witke, A Karameris, A Kotanidou, D Bouros, et al. Gelsolin expression is necessary for the development of modelled pulmonary inflammation and fibrosis Thorax, June 1, 2009; 64(6): 467 - 475. [Abstract] [Full Text] [PDF]

				P. F. Mercer, R. H. Johns, C. J. Scotton, M. A. Krupiczojc, M. Konigshoff, D. C. J. Howell, R. J. McAnulty, A. Das, A. J. Thorley, T. D. Tetley, et al. Pulmonary Epithelium Is a Prominent Source of Proteinase-activated Receptor-1-inducible CCL2 in Pulmonary Fibrosis Am. J. Respir. Crit. Care Med., March 1, 2009; 179(5): 414 - 425. [Abstract] [Full Text] [PDF]

				M R Looney, C T Esmon, and M A Matthay Role of coagulation pathways and treatment with activated protein C in hyperoxic lung injury Thorax, February 1, 2009; 64(2): 114 - 120. [Abstract] [Full Text] [PDF]

				R. C. Chambers Abnormal wound healing responses in pulmonary fibrosis: focus on coagulation signalling Eur. Respir. Rev., December 1, 2008; 17(109): 130 - 137. [Abstract] [Full Text] [PDF]

				R. M. du Bois and T. E. King Jr Elucidating the causes and examining the latest clinical findings in pulmonary fibrosis: recent progress and future objectives Eur. Respir. Rev., December 1, 2008; 17(109): 168 - 170. [Full Text] [PDF]

				L. O. Mosnier, B. V. Zlokovic, and J. H. Griffin The cytoprotective protein C pathway Blood, April 15, 2007; 109(8): 3161 - 3172. [Abstract] [Full Text] [PDF]

				J. Chen, Z. Chen, N. R. Chintagari, M. Bhaskaran, N. Jin, T. Narasaraju, and L. Liu Alveolar type I cells protect rat lung epithelium from oxidative injury J. Physiol., May 1, 2006; 572(3): 625 - 638. [Abstract] [Full Text] [PDF]

				H. Fujimoto, E. C. Gabazza, O. Taguchi, Y. Nishii, H. Nakahara, N. E. Bruno, C. N. D'Alessandro-Gabazza, M. Kasper, Y. Yano, M. Nagashima, et al. Thrombin-Activatable Fibrinolysis Inhibitor Deficiency Attenuates Bleomycin-Induced Lung Fibrosis Am. J. Pathol., April 1, 2006; 168(4): 1086 - 1096. [Abstract] [Full Text] [PDF]

				S. Weijer, C. W. Wieland, S. Florquin, and T. van der Poll A thrombomodulin mutation that impairs activated protein C generation results in uncontrolled lung inflammation during murine tuberculosis Blood, October 15, 2005; 106(8): 2761 - 2768. [Abstract] [Full Text] [PDF]

				D. C.J. Howell, R. H. Johns, J. A. Lasky, B. Shan, C. J. Scotton, G. J. Laurent, and R. C. Chambers Absence of Proteinase-Activated Receptor-1 Signaling Affords Protection from Bleomycin-Induced Lung Inflammation and Fibrosis Am. J. Pathol., May 1, 2005; 166(5): 1353 - 1365. [Abstract] [Full Text] [PDF]

				H. Yuda, Y. Adachi, O. Taguchi, E. C. Gabazza, O. Hataji, H. Fujimoto, S. Tamaki, K. Nishikubo, K. Fukudome, C. N. D'Alessandro-Gabazza, et al. Activated protein C inhibits bronchial hyperresponsiveness and Th2 cytokine expression in mice Blood, March 15, 2004; 103(6): 2196 - 2204. [Abstract] [Full Text] [PDF]

				A. W. Rijneveld, S. Weijer, S. Florquin, C. T. Esmon, J. C. M. Meijers, P. Speelman, P. H. Reitsma, H. Ten Cate, and T. van der Poll Thrombomodulin mutant mice with a strongly reduced capacity to generate activated protein C have an unaltered pulmonary immune response to respiratory pathogens and lipopolysaccharide Blood, March 1, 2004; 103(5): 1702 - 1709. [Abstract] [Full Text] [PDF]

				S. Idell The Matrix Unloaded: Aerosolized Heparin or Urokinase for Pulmonary Fibrosis Am. J. Respir. Crit. Care Med., December 1, 2003; 168(11): 1268 - 1269. [Full Text] [PDF]

				A. Gunther, N. Lubke, M. Ermert, R. T. Schermuly, N. Weissmann, A. Breithecker, P. Markart, C. Ruppert, K. Quanz, L. Ermert, et al. Prevention of Bleomycin-induced Lung Fibrosis by Aerosolization of Heparin or Urokinase in Rabbits Am. J. Respir. Crit. Care Med., December 1, 2003; 168(11): 1358 - 1365. [Abstract] [Full Text] [PDF]

				R.C. Chambers Role of coagulation cascade proteases in lung repair and fibrosis Eur. Respir. J., September 20, 2003; 22(44_suppl): 33s - 35s. [Full Text] [PDF]

				H. Fujimoto, E. C. Gabazza, O. Hataji, H. Yuda, C. N. D'Alessandro-Gabazza, M. Nakano, O. E. Franco, T. Hayashi, K. Suzuki, Y. Adachi, et al. Thrombin-activatable Fibrinolysis Inhibitor and Protein C Inhibitor in Interstitial Lung Disease Am. J. Respir. Crit. Care Med., June 15, 2003; 167(12): 1687 - 1694. [Abstract] [Full Text] [PDF]

				S. Shimizu, E. C. Gabazza, O. Taguchi, H. Yasui, Y. Taguchi, T. Hayashi, M. Ido, T. Shimizu, T. Nakagaki, H. Kobayashi, et al. Activated Protein C Inhibits the Expression of Platelet-derived Growth Factor in the Lung Am. J. Respir. Crit. Care Med., May 15, 2003; 167(10): 1416 - 1426. [Abstract] [Full Text] [PDF]

				M. J. Tobin Compliance (COMmunicate PLease wIth Less Abbreviations, Noun Clusters, and Exclusiveness) Am. J. Respir. Crit. Care Med., December 15, 2002; 166(12): 1534 - 1536. [Full Text] [PDF]

				E. C. Gabazza, O. Taguchi, Y. Adachi, E. C. Gabazza, O. Taguchi, and Y. Adachi BLEOMYCIN-INDUCED LUNG FIBROSIS: THE AUTHORS SHOULD HAVE USED ANOTHER METHOD TO INDUCE PULMONARY LESIONS RESEMBLING HUMAN IDIOPATHIC PULMONARY FIBROSIS Am. J. Respir. Crit. Care Med., March 15, 2002; 165(6): 845b - 846. [Full Text]

				M. J. TOBIN Tuberculosis, Lung Infections, Interstitial Lung Disease, and Socioeconomic Issues in AJRCCM 2001 Am. J. Respir. Crit. Care Med., March 1, 2002; 165(5): 631 - 641. [Full Text] [PDF]